MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/jca.21968

Медицинская библиотека · Journal of clinical apheresis · 2022

Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy.

Kruse Robert L, Albayda Jemima, Vozniak Sonja O, Lawrence Courtney E, Goel Ruchika, Lokhandwala Parvez M, Ness Paul M, Tobian Aaron A R, Bloch Evan M, Crowe Elizabeth P

СтатьяОбзорПеревод в очереди

Аннотация

INTRODUCTION

Necrotizing autoimmune myopathy (NAM) is strongly associated with pathognomonic autoantibodies targeting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) or signal recognition particle (SRP), whose levels in turn are correlated with serum creatine kinase (CK) and necrosis. Thus, NAM may be amenable to therapeutic plasma exchange (TPE) to remove pathogenic antibodies and improve patient symptoms.

METHODS

A retrospective case series and literature review of patients presenting with NAM and undergoing treatment with TPE was performed. Clinical data including patient demographics, symptoms, physical exam findings, muscle biopsy, lower extremity imaging, prior therapy, and duration from diagnosis to TPE initiation were collected retrospectively for adult patients with NAM treated with TPE after failing to respond to immunomodulatory therapy. Laboratory data including change in CK levels and myositis-specific antibody titers from baseline were measured in some patients.

RESULTS

Six patients (median age at diagnosis 52.5 years, interquartile range [IQR] 35.8-64.5 years, four male/two female) underwent a median of 7.5 (IQR: 5-10) TPE procedures with 5% albumin as replacement. All patients exhibited a statistically significant reduction in CK level from pre-TPE baseline (range: 43.0%-58.7% reduction). Responses in this cohort were best in patients with antibodies targeting HMGCR and SRP, which are most strongly associated with NAM. These results compare favorably to a literature review of NAM patients (n = 19) treated with TPE, who also exhibited positive clinical and laboratory responses across varying treatment lengths.

CONCLUSION

TPE can play a role in the management of NAM, particularly in patients with HMGCR or SRP antibodies who are refractory to pharmacologic immunosuppression.

Для цитирования: Kruse Robert L, Albayda Jemima, Vozniak Sonja O, Lawrence Courtney E, Goel Ruchika, Lokhandwala Parvez M, Ness Paul M, Tobian Aaron A R, Bloch Evan M, Crowe Elizabeth P. Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy.. Journal of clinical apheresis. 2022. DOI: 10.1002/jca.21968.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.